Privium Fund Management B.V. Buys 42,468 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL

Privium Fund Management B.V. grew its stake in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 16.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 294,142 shares of the company’s stock after purchasing an additional 42,468 shares during the period. Privium Fund Management B.V. owned about 0.11% of Autolus Therapeutics worth $674,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Knott David M Jr bought a new position in Autolus Therapeutics in the 1st quarter valued at approximately $651,000. Atle Fund Management AB increased its holdings in shares of Autolus Therapeutics by 130.5% during the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after buying an additional 625,817 shares in the last quarter. Armistice Capital LLC lifted its stake in shares of Autolus Therapeutics by 19.6% in the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock valued at $17,050,000 after acquiring an additional 1,800,000 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Autolus Therapeutics by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 524,872 shares of the company’s stock valued at $814,000 after acquiring an additional 168,650 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Autolus Therapeutics by 67.2% during the 1st quarter. Exchange Traded Concepts LLC now owns 69,993 shares of the company’s stock worth $108,000 after acquiring an additional 28,127 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Trading Up 4.9%

AUTL stock opened at $1.70 on Tuesday. The firm has a market cap of $452.44 million, a PE ratio of -2.02 and a beta of 1.84. The stock has a 50-day moving average price of $1.58 and a 200-day moving average price of $1.79. Autolus Therapeutics PLC Sponsored ADR has a 1-year low of $1.11 and a 1-year high of $4.79.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. On average, analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Wells Fargo & Company cut their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $9.12.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.